Phase IIa, Randomised, Controlled, OpenLabel Trial of Rosuvastatin for the Prevention of AminoglycosideInduced Kidney Toxicity in Children with Cystic Fibrosis
Phase of Trial: Phase II
Latest Information Update: 15 Sep 2016
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Kidney disorders
- Focus Pharmacodynamics
- Acronyms PROteKT
- 10 Jun 2017 Biomarkers information updated
- 02 Sep 2016 Status changed from recruiting to completed.
- 28 Jan 2016 Accrual to date is 36% according to United Kingdom Clinical Research Network record.